Carla Simone Moreira Freitas1,2,*, Fabiana Rocha-Silva2, Thaís Almeida Marques-Silva2, Ana Carolina Ribeiro de Oliveira1, Sérgio Gomes da Silva1,3,4, Fabrizio dos Santos Cardoso1,5, Aleida Nazareth Soares2
Canadian Journal of Urology, Vol.33, No.4, pp. 827-839, 2026, DOI:10.32604/cju.2026.069559
- 21 August 2026
Abstract Background: Androgen deprivation therapy (ADT) is widely employed in the management of advanced prostate cancer, with luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide and goserelin being common options. However, pharmacological and metabolic differences between these agents may affect the efficacy of hormonal suppression and adverse event profiles. This study compared the effects of leuprolide (22.5 and 45 mg) and goserelin (10.8 mg) on prostate-specific antigen (PSA) and testosterone reduction, as well as their metabolic and cardiovascular impacts and the influence of genetic variants on therapeutic response. Methods: A prospective, randomized, controlled study was conducted… More >